Challenges and solutions for therapeutic TCR ‐based agents
Immunological Reviews · 2023-11 · 320 (1) · 58-82
DOI: 10.1111/imr.13233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 16.07.2023. Verfasst von Manish Malviya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Recent development of methods to discover and engineer therapeutic T‐cell receptors (TCRs) or antibody mimics of TCRs, and to understand their immunology and pharmacology, lag two decades behind therapeutic antibodies. Yet we have every expectation that TCR‐based agents will be similarly important contributors to the treatment of a variety of medical conditions, especially cancers. TCR engineered cells, soluble TCRs and their derivatives, TCR‐mimic antibodies, and TCR‐based CAR T cells promise the possibility of highly specific drugs that can expand the scope of immunologic agents to recognize intracellular targets, including mutated proteins and undruggable transcription factors, not accessible by traditional antibodies. Hurdles exist regarding discovery, specificity, pharmacokinetics, and best modality of use that will need to be overcome before the full potential of TCR‐based agents is achieved. HLA restriction may limit each agent to patient subpopulations and off‐target reactivities remain important barriers to widespread development and use of these new agents. In this review we discuss the unique opportunities for these new classes of drugs, describe their unique antigenic targets, compare them to traditional antibody therapeutics and CAR T cells, and review the various obstacles that must be overcome before full application of these drugs can be realized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
- Physiology, Biophysics & Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York City, New York, USA.
- Weill-Cornell Medicine, Rockefeller University, Sloan Kettering Institute, Medical Scientist Training Program, New York City, New York, USA.
- Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, New York City, New York, USA.
ORCID-Profile: Manish Malviya, Patrick Wallisch, David A Scheinberg
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023). Challenges and solutions for therapeutic TCR ‐based agents. Immunological Reviews, 320(1), 58-82. https://doi.org/10.1111/imr.13233
Vancouver
Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, et al. Challenges and solutions for therapeutic TCR ‐based agents. Immunological Reviews. 2023;320(1):58-82. doi:10.1111/imr.13233
BibTeX
@article{Malviya2023,
author = {Malviya, Manish and Aretz, Zita E H and Molvi, Zaki and Lee, Jayop and Pierre, Stephanie and Wallisch, Patrick and Dao, Tao and Scheinberg, David A},
title = {Challenges and solutions for therapeutic TCR ‐based agents},
journal = {Immunological Reviews},
year = {2023},
volume = {320},
number = {1},
pages = {58--82},
doi = {10.1111/imr.13233}
}
EUVIMED